Open Calls for Input and Feedback


Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

Emgality (galcanezumab)

Therapeutic Area: Prevention of migraine
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

 

Myinfla (colchicine)

Therapeutic Area: Atherothrombotic events in coronary artery disease
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

 

Ngenla (somatrogon)

Therapeutic Area: Growth hormone deficiency
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

 

Opsynvi (macitentan and tadalafil)

Therapeutic Area: Pulmonary arterial hypertension
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: Narcolepsy
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Advanced endometrial cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Spinal Muscular Atrophy
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Non-small cell lung cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Phenylketonuria
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Cystic fibrosis, F508del CFTR mutation, 6 years and older
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Alzheimer’s disease
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Amyotrophic lateral sclerosis (ALS)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: advanced or metastatic renal cell carcinoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Lambert-Eaton Myasthenic Syndrome, adults
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: